ClinicalTrials.gg
CompletedNCT00467766Updated May 7, 2007

Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease

An interventional study of Psychosocial information, counseling, and support and Donepezil (Aricept) in Alzheimer Disease and Caregivers, sponsored by Pfizer. Completed at 3 sites in 3 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2007-05-07.

Sponsored by Pfizer · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
5th of 58
300 · median 79
Started
1999
with 2 others
No phase
6 of 60
none open now
Registered
14th of 60
by date
Lead sponsor
4 of 60
Pfizer

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 5th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 1999, is one of 6 with no phase, and was the 14th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

A unique multinational study was conducted simultaneously in the USA, England and Australia. The goals of the study were to answer two questions: Does psychosocial support for the family enhance the effectiveness of drug treatment for Alzheimer's disease? Is the added value of psychosocial support the same in all 3 countries?

Read the detailed description

This study is a single-blind prospective randomized trial with 150 patient/caregiver pairs (50 in each country). Eligibility criteria at baseline require that the primary caregiver is the spouse of the patient; the patient must have a diagnosis of AD, be in the in mild to moderate stage of dementia, be living with the caregiver, and be willing to take Donepezil (Aricept). These participants were randomly assigned to one of two groups: in one group, the intervention consists of drug treatment for the patient plus psychosocial intervention for the caregiver; in the other group the intervention consists solely of drug treatment for the patient.

The intervention for the caregiver consists of 5 scheduled individual and family counseling sessions within 3 months of baseline, and unlimited consultations on request. Assessments were conducted every 3 months for the first year and every 6 months for a second year. There are 3 sources of data: an interview of the caregiver by an independent rater, an assessment of the patient, and a count of the amount of medication used. Thus we will be able to assess the effect of adding counseling to medication for the caregiver, for the patient, and on compliance with medication use.

03

Conditions studied

  • Alzheimer Disease
  • Caregivers

Keywords

  • dementia
  • Counseling
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals diagnosed with mild to moderate stage Alzheimer's disease and their spouse caregivers

Exclusion criteria

Exclusion Criteria:

  • Severe psychological or physical illness
  • Unwillingness by either spouse to participate in all aspects of the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single
Enrollment
300 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Caregiver: Changes in depression, measured with the Beck Depression Inventory

    Time frame: every 3 months for the first year, and every 6 months for the second year

  2. Caregiver: Changes in social support satisfaction, measured with the Stokes Social Network Scale

    Time frame: every 3 months for the first year, and every 6 months for the second year

  3. Patient: Changes in cognition measured by ADAS-cog

    Time frame: every 3 months for the first year, and every 6 months for the second year

  4. Patient: Changes in abilities with activities of daily living measured by ADCS-ADL

    Time frame: every 3 months for the first year, and every 6 months for the second year

Secondary outcomes

  1. Caregiver: Changes in reactions to patient behavior, physical health, family conflict and sense of mastery

    Time frame: every 3 months for the first year, and every 6 months for the second year

  2. Patient: Time to nursing home placement

07

Study locations

3 sites
  • Aging and Dementia Research Center, Silberstein Institute, NYU School of Medicine
    New York, New York 10016, United States
  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
  • University of Manchester, Division of Psychiatry
    Manchester, M23 9LT, United Kingdom
08

References and documents

Publications

  • Mittelman MS, Haley WE, Clay OJ, Roth DL. Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease. Neurology. 2006 Nov 14;67(9):1592-9. doi: 10.1212/01.wnl.0000242727.81172.91. PubMed 17101889 ↗
  • Mittelman MS, Roth DL, Coon DW, Haley WE. Sustained benefit of supportive intervention for depressive symptoms in caregivers of patients with Alzheimer's disease. Am J Psychiatry. 2004 May;161(5):850-6. doi: 10.1176/appi.ajp.161.5.850. PubMed 15121650 ↗
  • Jang Y, Clay OJ, Roth DL, Haley WE, Mittelman MS. Neuroticism and longitudinal change in caregiver depression: impact of a spouse-caregiver intervention program. Gerontologist. 2004 Jun;44(3):311-7. doi: 10.1093/geront/44.3.311. PubMed 15197285 ↗
  • Roth DL, Mittelman MS, Clay OJ, Madan A, Haley WE. Changes in social support as mediators of the impact of a psychosocial intervention for spouse caregivers of persons with Alzheimer's disease. Psychol Aging. 2005 Dec;20(4):634-44. doi: 10.1037/0882-7974.20.4.634. PubMed 16420138 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 1999 and a completion of Jun 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2007
First posted
May 1, 2007
Start
Jul 1999
CompletionActual
Jun 2003
Last update
May 7, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00467766
Lead sponsor
Pfizer
First posted
May 1, 2007
Start date
Jul 1999
Completion
Jun 2003
Last update
May 7, 2007

Study contacts

Mary S. Mittelman, DrPH
principal investigator · NYU School of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion